Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Sapoutzis

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Anticancer Research|June 25, 2003
Pro-gastrin-releasing peptide (Pro-GRP), a tumor marker for small cell lung cancerG M Oremek, N Sapoutzis
Anticancer Research|June 25, 2003
Phospholipids, tumour marker and beta-CrossLaps in diagnosis of gastric carcinomaG M Oremek, N Sapoutzis, M Lorenz
Klinicheskaia Meditsina|September 22, 2007
[The significance of TU M2-PK tumor marker for lung cancer diagnostics]G Oremek, R Kukshaĭte, N Sapoutzis, et al.
Anticancer Research|June 25, 2003
Complexed PSA in routine diagnosisG M Oremek, N Sapoutzis, F Eden, et al.
Anticancer Research|June 25, 2003
Pyruvate kinase type tumor M2 plasma levels in patients afflicted with rheumatic diseasesG M Oremek, R Müller, N Sapoutzis, et al.
Anticancer Research|June 25, 2003
Tumor marker pyruvate kinase type tumor M2 in patients suffering from diabetic nephropathyG M Oremek, F Rutner, N Sapoutzis, et al.
Anticancer Research|June 25, 2003
Diagnostic value of bone and tumour markers in patients with malignant diseasesG M Oremek, A Weis, N Sapoutzis, et al.
Anticancer Research|May 1, 2001
Value of tumor M2 (Tu M2-PK) in patients with renal carcinomaG M Oremek, N Sapoutzis, W Kramer, et al.
Anticancer Research|June 25, 2003
Pre-analytical problems in the measurement of tumor type pyruvate kinase (tumor M2-PK)G M Oremek, F Gerstmeier, H Sauer-Eppel, et al.
Anticancer Research|June 25, 2003
Tumor M2-PK levels in haematological malignanciesG M Oremek, St Rox, P Mitrou, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Anticancer Research|June 25, 2003
Pro-gastrin-releasing peptide (Pro-GRP), a tumor marker for small cell lung cancerG M Oremek, N Sapoutzis
Anticancer Research|June 25, 2003
Phospholipids, tumour marker and beta-CrossLaps in diagnosis of gastric carcinomaG M Oremek, N Sapoutzis, M Lorenz
Klinicheskaia Meditsina|September 22, 2007
[The significance of TU M2-PK tumor marker for lung cancer diagnostics]G Oremek, R Kukshaĭte, N Sapoutzis, et al.
Anticancer Research|June 25, 2003
Complexed PSA in routine diagnosisG M Oremek, N Sapoutzis, F Eden, et al.
Anticancer Research|June 25, 2003
Pyruvate kinase type tumor M2 plasma levels in patients afflicted with rheumatic diseasesG M Oremek, R Müller, N Sapoutzis, et al.
Anticancer Research|June 25, 2003
Tumor marker pyruvate kinase type tumor M2 in patients suffering from diabetic nephropathyG M Oremek, F Rutner, N Sapoutzis, et al.
Anticancer Research|June 25, 2003
Diagnostic value of bone and tumour markers in patients with malignant diseasesG M Oremek, A Weis, N Sapoutzis, et al.
Anticancer Research|May 1, 2001
Value of tumor M2 (Tu M2-PK) in patients with renal carcinomaG M Oremek, N Sapoutzis, W Kramer, et al.
Anticancer Research|June 25, 2003
Pre-analytical problems in the measurement of tumor type pyruvate kinase (tumor M2-PK)G M Oremek, F Gerstmeier, H Sauer-Eppel, et al.
Anticancer Research|June 25, 2003
Tumor M2-PK levels in haematological malignanciesG M Oremek, St Rox, P Mitrou, et al.
Pageof 1